{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-034467","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.311521+00:00","generated_at":"2026-05-16T20:59:55.656746+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"DiaMedica Q3 net loss $8.6M; ReMEDy2 trial at 50% enrollment","bullets":["Net loss $8.6M in Q3 2025, up from $6.3M a year ago; R&D expense $6.4M, up from $5.0M.","Cash and short-term investments $55.3M as of Sept 30, 2025; funded into 2H 2027.","ReMEDy2 Phase 2/3 AIS trial enrollment nearing 50% of 200-patient interim target.","Preeclampsia IST Part 1a expansion cohort enrolling; Part 3 fetal growth restriction screening starting soon.","Pre-IND meeting with FDA on DM199 for preeclampsia held; update after minutes received."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-034467","json":"https://secwatch.observer/filing/0001437749-25-034467.json","markdown":"https://secwatch.observer/filing/0001437749-25-034467.md","text":"https://secwatch.observer/filing/0001437749-25-034467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925034467/0001437749-25-034467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925034467/dmtp20251112_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:59:55.656746+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}